Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 24, 2009

Monsanto Buys Broader Rights to Devgen Technolgies for $26.5M

Monsanto Buys Broader Rights to Devgen Technolgies for $26.5M

Monsanto purchases broader rights to Devgen technologies

  • Monsanto and Devgen updated their research and technology exchange agreement, originally signed in 2007, giving Mosanto broader rights to Devgen's technology in exchange for €20 million ($26.5 million) in cash.

    "We welcome the additional interest of Monsanto in broadening its access to Devgen trait technology in selected crops," says Thierry Bogaert, Devgen's CEO. "This agreement strengthens our cash position without affecting Devgen's rights in its crops of interest and reinforces Devgen's ability to execute its downstream trait and seed business plan."

    Monsanto and Devgen's original agreement in February, 2007 was a five-year R&D agreement and a five-year technology exchange agreement, designed to allow each company to share technology advances for use in their respective crop areas of interest. Devgen purchased Monsanto's rice, sunflower, sorghum, and pearl millet businesses in the Indian subcontinent and Southeast Asia in late 2007.ADNFCR-2184-ID-19138415-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »